1. Home
  2. UTHR vs GPN Comparison

UTHR vs GPN Comparison

Compare UTHR & GPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$586.57

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

GPN

Global Payments Inc.

HOLD

Current Price

$72.35

Market Cap

21.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTHR
GPN
Founded
1996
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
25.1B
21.8B
IPO Year
1999
2000

Fundamental Metrics

Financial Performance
Metric
UTHR
GPN
Price
$586.57
$72.35
Analyst Decision
Buy
Buy
Analyst Count
14
21
Target Price
$567.57
$92.50
AVG Volume (30 Days)
554.5K
2.7M
Earning Date
04-29-2026
05-05-2026
Dividend Yield
N/A
1.41%
EPS Growth
13.07
N/A
EPS
27.86
5.78
Revenue
$1,483,300,000.00
$3,975,163,000.00
Revenue This Year
$7.08
$63.81
Revenue Next Year
$14.32
$6.27
P/E Ratio
$20.81
$12.25
Revenue Growth
2.38
17.92
52 Week Low
$272.18
$62.45
52 Week High
$607.89
$90.64

Technical Indicators

Market Signals
Indicator
UTHR
GPN
Relative Strength Index (RSI) 63.89 58.34
Support Level $464.92 $71.24
Resistance Level $607.89 $73.21
Average True Range (ATR) 17.12 2.54
MACD -0.23 0.97
Stochastic Oscillator 63.42 92.66

Price Performance

Historical Comparison
UTHR
GPN

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

About GPN Global Payments Inc.

Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.

Share on Social Networks: